haloperidol has been researched along with Recrudescence in 102 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia." | 9.10 | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 9.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 8.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "Olanzapine was superior to haloperidol in the maintenance therapy of schizophrenia and related psychoses." | 7.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 7.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 7.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "We report on a 41 year old woman, who after 750 mg mefloquine, a newer antimalarial agent, developed a psychosis with dizziness, confusion and delusions." | 7.68 | [Psychotic episode caused by prevention of malaria with mefloquine. A case report]. ( Folkerts, H; Kuhs, H, 1992) |
| "Two typical recurrent episodes of neuroleptic malignant syndrome (NMS) in the same patient are described." | 5.27 | Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. ( Hermesh, H; Huberman, M; Kott, E; Radvan, H, 1984) |
| "Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia." | 5.10 | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003) |
| "To more clearly clarify the efficacy of the atypical antipsychotics compared to conventional antipsychotics, we add data on the outcome of patients diagnosed with schizophrenia from two large, international clinical trials comparing olanzapine with haloperidol (n = 1996) and olanzapine with risperidone (n = 339)." | 5.10 | Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. ( Berg, PH; Glick, ID, 2002) |
| "The aim of the study was to examine effects of haloperidol on the relationships between neuropsychological measures of frontal lobe functioning and the schizophrenia syndromes of psychomotor poverty and disorganization." | 5.09 | Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes. ( Allen, DN; Anastasiou, A; Gilbertson, M; Goldstein, G; van Kammen, DP, 2000) |
| "Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride." | 5.07 | A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. ( Ancill, R; Awad, G; Bakish, D; Beaudry, P; Bloom, D; Chandrasena, R; Das, M; Durand, C; Elliott, D; Lapierre, YD, 1992) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 5.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 4.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands." | 3.85 | Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| " First, he received 15 mg per day of haloperidol, and seven days later he developed priapism." | 3.80 | [Antipsychotic-induced priapism and management challenges: a case report]. ( Doufik, J; Ghanmi, J; Khalili, L; Otheman, Y; Ouanass, A, 2014) |
| " Following initial improvement, she developed delayed rhabdomyolysis then haloperidol-induced neuroleptic malignant syndrome, which was treated with a total of 50 mg." | 3.78 | Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. ( Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC, 2012) |
| "Olanzapine was superior to haloperidol in the maintenance therapy of schizophrenia and related psychoses." | 3.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 3.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 3.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced." | 3.69 | A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997) |
| "We report on a 41 year old woman, who after 750 mg mefloquine, a newer antimalarial agent, developed a psychosis with dizziness, confusion and delusions." | 3.68 | [Psychotic episode caused by prevention of malaria with mefloquine. A case report]. ( Folkerts, H; Kuhs, H, 1992) |
| "112 patients were treated with a mean dosage of 4." | 2.76 | Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Kühn, KU; Mayr, A; Meyer, S; Möller, HJ; Riedel, M; Schennach-Wolff, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2011) |
| "In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation." | 2.76 | A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. ( Cunqueiro, K; Devanand, DP; Marder, K; Pelton, GH; Sackeim, HA, 2011) |
| "haloperidol in treatment of acute migraine headache in a double-blind, randomized, placebo-controlled study design." | 2.72 | Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. ( Honkaniemi, J; Liimatainen, S; Rainesalo, S; Sulavuori, S, 2006) |
| "Haloperidol decanoate 100 mg was administered on a weekly basis for the first 4 weeks." | 2.68 | A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. ( Chang, WH; Jann, MW; Lin, HN; Piao-Chien, C; Wei, FC, 1996) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Children with Sydenham's chorea and PANDAS (Pediatric autoimmune neuropsychiatric disorders associated with streptococcal throat infections) share an array of neuropsychiatric symptoms and distinguishing one from the other, especially at onset can prove challenging." | 2.42 | Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature. ( Schoeman, JF; van Toorn, R; Weyers, HH, 2004) |
| " In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance." | 2.38 | Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993) |
| "The treatment of Sydenham's chorea was based on neuroleptics." | 1.46 | [Exceptionally good response to sodium valproate in patients with recurrent Sydenham's chorea]. ( Belahsen, MF; Bouchal, S; Ouali, O, 2017) |
| "Treating schizophrenia is costly for health systems." | 1.43 | Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "Aripiprazole is a new generation antipsychotic drug that shows a partial agonistic activity at D(2) and 5-HT(1A) receptors." | 1.38 | Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. ( Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H, 2012) |
| "Hyperventilation syndrome has often occurred as a reaction to anxiety and stress." | 1.35 | [Hyperventilation syndrome before induction of and after awakening from general anesthesia]. ( Hanaoka, K; Honda, M; Itou, Y; Mizuno, J; Momoeda, K; Morita, S, 2009) |
| "We report a case of severe neuroleptic malignant syndrome with hyperthermia, rhabdomyolysis and hepatic failure where we applied endovascular cooling in order to reverse hyperthermia." | 1.35 | Endovascular cooling in a patient with neuroleptic malignant syndrome. ( Diedler, J; Mellado, P; Veltkamp, R, 2008) |
| "As the pneumothorax was completely reabsorbed, no chest drains were inserted and the patient was transferred to our toxicological intensive care unit." | 1.34 | ["Usual" cannabis abuse producing an unusual incident]. ( Heppner, HJ; Schmitt, K; Sieber, C, 2007) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| "Two patients suffering from Tourette's Syndrome who had developed episodes of continual motor tics that lasted from minutes to hours, were non-suppressible and intruded into normal functioning, were treated with an increase in the dose of haloperidol, in one case with the addition of clonazepam." | 1.29 | Tics status. ( Chee, KY; Sachdev, P; Wilson, A, 1996) |
| "Haloperidol treatment was withdrawn for up to 6 weeks and patients were evaluated for symptom recurrence." | 1.29 | Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. ( Gurklis, J; Kelley, ME; McAllister, CG; Miller, AL; Peters, JL; Rehn, TJ; van Kammen, DP; Yao, J, 1995) |
| "A case of recurrent neuroleptic malignant syndrome (NMS) occurring in a 29-year-old man with mild mental handicap and a superadded psychotic disorder is described." | 1.28 | Recurrent neuroleptic malignant syndrome in a man with mild mental handicap. ( Bambrick, M; Wilson, D, 1992) |
| "Individuals with mental retardation are thought to be at greater risk, and some recommendations were offered to prevent recurrence." | 1.28 | Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation. ( Boyd, RD, 1992) |
| " The study indicates that haloperidol decanoate even in low dosage is effective maintenance therapy is preventing relapse." | 1.28 | Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. ( Youssef, HA, 1991) |
| "The natural course of untreated neuroleptic malignant syndrome (NMS) does not usually exceed 3 weeks." | 1.28 | [Protracted recurrent neuroleptic malignant syndrome]. ( Delerue, O; Destée, A, 1990) |
| "Two typical recurrent episodes of neuroleptic malignant syndrome (NMS) in the same patient are described." | 1.27 | Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. ( Hermesh, H; Huberman, M; Kott, E; Radvan, H, 1984) |
| "The determinants of relapse have been elusive." | 1.26 | Low serum neuroleptic levels predict relapse in schizophrenic patients. ( Brown, WA; Chisholm, E; Laughren, T; Williams, BW, 1982) |
| "Neurologic complications of systemic lupus erythematosus (SLE) are common, but chorea is rare." | 1.25 | Clinical features of chorea associated with systemic lupus erythematosus. ( Lusins, JO; Szilagyi, PA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (28.43) | 18.7374 |
| 1990's | 36 (35.29) | 18.2507 |
| 2000's | 20 (19.61) | 29.6817 |
| 2010's | 15 (14.71) | 24.3611 |
| 2020's | 2 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Bogers, JPAM | 1 |
| Hambarian, G | 1 |
| Walburgh Schmidt, N | 1 |
| Vermeulen, JM | 1 |
| de Haan, L | 2 |
| Herrera-Huerta, CA | 1 |
| Hernández-Salas, LP | 1 |
| Magallanes-Cano, EM | 1 |
| Einarson, TR | 2 |
| Bereza, BG | 2 |
| Tedouri, F | 1 |
| Van Impe, K | 2 |
| Denee, TR | 1 |
| Dries, PJT | 1 |
| Bouchal, S | 1 |
| Ouali, O | 1 |
| Belahsen, MF | 1 |
| Uys, H | 1 |
| Oluwole, LO | 1 |
| Dada, MU | 1 |
| Obadeji, A | 1 |
| Doufik, J | 1 |
| Otheman, Y | 1 |
| Khalili, L | 1 |
| Ghanmi, J | 1 |
| Ouanass, A | 1 |
| Anheim, M | 1 |
| Dowsey-Limousin, P | 1 |
| Krack, P | 1 |
| Chabardès, S | 1 |
| Benabid, AL | 1 |
| Pollak, P | 1 |
| Maia-Lopes, S | 1 |
| Goswami, P | 1 |
| Janicak, PG | 1 |
| Glick, ID | 2 |
| Marder, SR | 2 |
| Crandall, DT | 1 |
| McQuade, RD | 2 |
| Marcus, RN | 1 |
| Eudicone, JM | 1 |
| Assunção-Talbott, S | 1 |
| Dan, A | 1 |
| Bharadwaj, R | 1 |
| Grover, S | 1 |
| Marchione, P | 1 |
| Vento, C | 1 |
| Marianetti, M | 1 |
| Romeo, T | 1 |
| Amabile, GA | 1 |
| Giacomini, P | 1 |
| Mizuno, J | 1 |
| Morita, S | 1 |
| Itou, Y | 1 |
| Honda, M | 1 |
| Momoeda, K | 1 |
| Hanaoka, K | 1 |
| Lindner, LM | 1 |
| Marasciulo, AC | 1 |
| Farias, MR | 1 |
| Grohs, GE | 1 |
| Li, AY | 1 |
| Cong, S | 1 |
| Lu, H | 1 |
| Li, JJ | 1 |
| Zhao, L | 1 |
| Zivković, M | 1 |
| Mihaljević-Peles, A | 1 |
| Sagud, M | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Pekkan, G | 1 |
| Kilicoglu, A | 1 |
| Algin, DI | 1 |
| Schennach-Wolff, R | 1 |
| Jäger, M | 1 |
| Mayr, A | 1 |
| Meyer, S | 1 |
| Kühn, KU | 1 |
| Klingberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Schmitt, A | 1 |
| Schlösser, R | 1 |
| Schneider, F | 1 |
| Gaebel, W | 1 |
| Seemüller, F | 1 |
| Möller, HJ | 1 |
| Riedel, M | 1 |
| Kim, YD | 1 |
| Kim, JS | 1 |
| Song, IU | 1 |
| Lee, KS | 1 |
| Kim, YI | 1 |
| Devanand, DP | 1 |
| Pelton, GH | 1 |
| Cunqueiro, K | 1 |
| Sackeim, HA | 1 |
| Marder, K | 1 |
| Letmaier, M | 1 |
| Painold, A | 1 |
| Holl, AK | 1 |
| Grohmann, R | 1 |
| Vergin, H | 1 |
| Russell, T | 1 |
| Riazi, S | 1 |
| Kraeva, N | 1 |
| Steel, AC | 1 |
| Hawryluck, LA | 1 |
| Kopf, A | 1 |
| Köster, J | 1 |
| Schulz, A | 1 |
| Krömker, H | 1 |
| Becker, T | 1 |
| Kasper, S | 1 |
| Lerman, MN | 1 |
| Saha, A | 1 |
| Carson, WH | 1 |
| Ali, M | 1 |
| Archibald, D | 1 |
| Ingenito, G | 1 |
| Marcus, R | 1 |
| Pigott, T | 1 |
| Alevizos, B | 1 |
| Sluys, M | 1 |
| Güzelcan, Y | 1 |
| Casteelen, G | 1 |
| van Toorn, R | 1 |
| Weyers, HH | 1 |
| Schoeman, JF | 1 |
| Honkaniemi, J | 1 |
| Liimatainen, S | 1 |
| Rainesalo, S | 1 |
| Sulavuori, S | 1 |
| Heppner, HJ | 1 |
| Sieber, C | 1 |
| Schmitt, K | 1 |
| Diedler, J | 1 |
| Mellado, P | 1 |
| Veltkamp, R | 1 |
| Casiano, H | 1 |
| Globerman, D | 1 |
| Enns, MW | 1 |
| Brown, WA | 2 |
| Laughren, T | 2 |
| Chisholm, E | 1 |
| Williams, BW | 1 |
| Nishikawa, T | 1 |
| Tsuda, A | 1 |
| Tanaka, M | 1 |
| Koga, I | 1 |
| Uchida, Y | 1 |
| Hermesh, H | 2 |
| Huberman, M | 1 |
| Radvan, H | 1 |
| Kott, E | 1 |
| Manberg, PJ | 1 |
| Carter, RG | 1 |
| Sato, M | 1 |
| Chen, CC | 1 |
| Akiyama, K | 1 |
| Otsuki, S | 1 |
| Glazer, WM | 1 |
| Sheard, MH | 1 |
| McKay, B | 1 |
| van Kammen, DP | 12 |
| Agren, H | 1 |
| Yao, JK | 5 |
| O'Connor, DT | 1 |
| Gurklis, J | 3 |
| Peters, JL | 6 |
| Kelley, ME | 3 |
| Gurklis, JA | 1 |
| Gilbertson, MW | 2 |
| McAllister, CG | 1 |
| Rehn, TJ | 1 |
| Miller, AL | 1 |
| Yao, J | 4 |
| Forman, SD | 1 |
| Bissette, G | 1 |
| Nemeroff, CB | 1 |
| Lieberman, JA | 1 |
| Davis, JM | 1 |
| Kane, JM | 1 |
| Brauzer, B | 1 |
| Gierl, B | 1 |
| Schooler, N | 1 |
| Casey, DE | 1 |
| Hassan, M | 1 |
| Wei, FC | 1 |
| Jann, MW | 1 |
| Lin, HN | 1 |
| Piao-Chien, C | 1 |
| Chang, WH | 1 |
| Altamura, AC | 1 |
| Tacchini, GL | 1 |
| Maes, M | 1 |
| Sachdev, P | 1 |
| Chee, KY | 1 |
| Wilson, A | 1 |
| Modrego Pardo, P | 1 |
| Pérez Trullen, JM | 1 |
| Wirz-Justice, A | 1 |
| Cajochen, C | 1 |
| Nussbaum, P | 1 |
| Tran, PV | 1 |
| Dellva, MA | 1 |
| Tollefson, GD | 1 |
| Wentley, AL | 1 |
| Beasley, CM | 1 |
| Hanel, RA | 1 |
| Sandmann, MC | 1 |
| Kranich, M | 1 |
| De Bittencourt, PR | 1 |
| Ronchezel, MV | 1 |
| Hilario, MO | 1 |
| Forleo, LH | 1 |
| Len, CA | 1 |
| Terreri, MT | 1 |
| Vilanova, LC | 1 |
| Sole, D | 1 |
| Normann, C | 1 |
| Langosch, J | 1 |
| Schaerer, LO | 1 |
| Grunze, H | 1 |
| Walden, J | 1 |
| Allen, DN | 1 |
| Anastasiou, A | 1 |
| Goldstein, G | 1 |
| Gilbertson, M | 1 |
| Spencer, J | 1 |
| Azorin, JM | 1 |
| Berg, PH | 1 |
| Zwanzger, P | 1 |
| Ella, R | 1 |
| Keck, ME | 1 |
| Rupprecht, R | 1 |
| Padberg, F | 1 |
| Singh, MM | 1 |
| Kay, SR | 1 |
| Linn, MW | 1 |
| Caffey, EM | 1 |
| Klett, CJ | 1 |
| Hogarty, GE | 1 |
| Lamb, HR | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Deniker, P | 1 |
| Robbins, EL | 1 |
| Nagel, JD | 1 |
| Lusins, JO | 1 |
| Szilagyi, PA | 1 |
| Bambrick, M | 1 |
| Wilson, D | 1 |
| Steadman, P | 1 |
| Steinhauer, SR | 1 |
| Colbert, K | 1 |
| Zubin, J | 1 |
| Lapierre, YD | 1 |
| Ancill, R | 1 |
| Awad, G | 1 |
| Bakish, D | 1 |
| Beaudry, P | 1 |
| Bloom, D | 1 |
| Chandrasena, R | 1 |
| Das, M | 1 |
| Durand, C | 1 |
| Elliott, D | 1 |
| Kirkpatrick, B | 1 |
| Carpenter, WT | 1 |
| Maeda, K | 1 |
| Buchanan, RW | 1 |
| Breier, A | 1 |
| Tamminga, CA | 1 |
| Boyd, RD | 1 |
| Folkerts, H | 1 |
| Kuhs, H | 1 |
| Neylan, TC | 1 |
| Ruskin, PE | 1 |
| Nyman, G | 1 |
| Youssef, HA | 1 |
| Eklund, K | 1 |
| Forsman, A | 1 |
| Peters, J | 2 |
| van Kammen, WB | 2 |
| Neylan, T | 1 |
| Shaw, D | 1 |
| Linnoila, M | 2 |
| Cookson, JC | 1 |
| Tondo, L | 1 |
| Rudas, N | 1 |
| Altamura, CA | 1 |
| Colacurcio, F | 1 |
| Mauri, MC | 1 |
| Moro, AR | 1 |
| De Novellis, F | 1 |
| Delerue, O | 1 |
| Destée, A | 1 |
| Jolley, AG | 1 |
| Hirsch, SR | 1 |
| Morrison, E | 1 |
| McRink, A | 1 |
| Wilson, L | 1 |
| Nugent, A | 1 |
| Goetz, KL | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Crow, TJ | 1 |
| MacMillan, JF | 1 |
| Johnson, AL | 1 |
| Johnstone, EC | 1 |
| Migneco, G | 1 |
| Mascarella, A | 1 |
| Tripi, S | 1 |
| La Cascia, C | 1 |
| Navetta, A | 1 |
| Faraone, SV | 1 |
| Curran, JP | 1 |
| Faltus, F | 1 |
| Johnston, R | 1 |
| Bartkó, G | 1 |
| Mayláth, E | 1 |
| Herczeg, I | 1 |
| Huyse, F | 1 |
| van Schijndel, RS | 1 |
| Goldschmidt, TJ | 1 |
| Burch, EA | 1 |
| Gutnisky, G | 1 |
| Cabrera, JF | 1 |
| Körner, W | 1 |
| Müller-Oerlinghausen, B | 1 |
| Hoogstraten, MC | 1 |
| Lakke, JP | 1 |
| Zwarts, MJ | 1 |
| Kazamatsuri, H | 1 |
| Chien, CP | 1 |
| Cole, JO | 1 |
| Kenway, AK | 1 |
| Gallant, DM | 1 |
| Mielke, DH | 1 |
| Spirtes, MA | 1 |
| Swanson, WC | 1 |
| Bost, R | 1 |
| Shopsin, B | 1 |
| Gershon, S | 1 |
| Shenker, DM | 1 |
| Grossman, HJ | 1 |
| Klawans, HL | 1 |
| Payk, TR | 1 |
| Abuzzahab, FS | 1 |
| Ehlen, KJ | 1 |
| Geier, J | 1 |
| Krautheim, A | 1 |
| Fuchs, T | 1 |
| Carmichael, AJ | 1 |
| Gibson, JJ | 1 |
| Walls, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Behavioral Symptoms in Alzheimer's Disease[NCT00009217] | Phase 4 | 44 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Prospective, Double Blind, Randomized, Sham-Controlled, Clinical Trial to Evaluate The Safety And Efficacy Of Biometrics-Guided Magnetic EEG Resonance Therapy (MeRT) Treatment Of Post-Traumatic Stress Disorder With And Without Persistent Post-Concussive[NCT02990793] | 152 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
7 reviews available for haloperidol and Recrudescence
| Article | Year |
|---|---|
Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
Topics: Antipsychotic Agents; Drug Tapering; Haloperidol; Humans; Randomized Controlled Trials as Topic; Rec | 2023 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol | 2003 |
Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature.
Topics: Child; Chorea; Diagnosis, Differential; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examin | 2004 |
Prediction of outcome in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Growth Hormo | 1993 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre | 1993 |
Allergic contact dermatitis to bisphenol-A-glycidyldimethacrylate (BIS-GMA) dental resin associated with sensitivity to epoxy resin.
Topics: Bisphenol A-Glycidyl Methacrylate; Chronic Disease; Cross Reactions; Dermatitis, Allergic Contact; E | 1997 |
25 trials available for haloperidol and Recrudescence
| Article | Year |
|---|---|
Clinical observation on treatment of Tourette syndrome by integrative medicine.
Topics: Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th | 2009 |
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Mal | 2011 |
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2011 |
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; | 2003 |
Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; F | 2006 |
Prophylactic effect of neuroleptics in symptom-free schizophrenics.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Diazepam; Female; Haloperidol; Humans; Imipramine; Male | 1982 |
Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
Topics: Adult; Chronic Disease; Corticotropin-Releasing Hormone; Double-Blind Method; Haloperidol; Humans; M | 1994 |
Memory and plasma HVA changes in schizophrenia: are they episode markers?
Topics: Adult; Biomarkers; Cognition Disorders; Double-Blind Method; Haloperidol; Homovanillic Acid; Humans; | 1994 |
A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Fe | 1996 |
Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Topics: Adult; Antipsychotic Agents; Benztropine; Cross-Over Studies; Double-Blind Method; Frontal Lobe; Hal | 2000 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2002 |
Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study.
Topics: Adult; Aftercare; Attitude; Chlorpromazine; Chronic Disease; Cost-Benefit Analysis; Day Care, Medica | 1979 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study.
Topics: Age Factors; Aged; Antiemetics; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal | 1975 |
Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Topics: Adult; Arousal; Double-Blind Method; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; | 1992 |
A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1992 |
Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Double-Blind Method; Follow-Up Studies; Haloperi | 1991 |
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dys | 1991 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.
Topics: Administration, Oral; Basal Ganglia Diseases; Double-Blind Method; Drug Evaluation; Evaluation Studi | 1990 |
A randomised controlled trial of prophylactic neuroleptic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Female; Flu | 1986 |
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluatio | 1973 |
A double-blind comparison of pimozide and haloperidol in the treatment of recurrent anxiety states.
Topics: Adult; Anxiety; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Pimozide; | 1973 |
Penfluridol: an efficacious long-acting oral antipsychotic compound.
Topics: Acute Disease; Administration, Oral; Chromatography, Gas; Clinical Trials as Topic; Cooperative Beha | 1974 |
The current status of lithium in psychiatry.
Topics: Acute Disease; Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Depression; Female; Halop | 1974 |
70 other studies available for haloperidol and Recrudescence
| Article | Year |
|---|---|
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2017 |
[Exceptionally good response to sodium valproate in patients with recurrent Sydenham's chorea].
Topics: Adolescent; Anticonvulsants; Chorea; Female; Follow-Up Studies; Haloperidol; Humans; Recurrence; Rhe | 2017 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Self-inflicted bilateral orchidectomy precipitated by erotic bizarre delusions: a case report.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Prognosis; Recurrence; Schizophrenia, Parano | 2013 |
[Antipsychotic-induced priapism and management challenges: a case report].
Topics: Antipsychotic Agents; Benzodiazepines; Drug Substitution; Follow-Up Studies; Haloperidol; Hospitals, | 2014 |
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report.
Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; | 2015 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2016 |
Neuroleptic malignant syndrome with use of quetiapine in mental retardation.
Topics: Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Intellectu | 2009 |
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Antihypertensive Agents; Ataxia; Cerebellum; Dose-Res | 2009 |
[Hyperventilation syndrome before induction of and after awakening from general anesthesia].
Topics: Anesthesia, Epidural; Anesthesia, General; Antipsychotic Agents; Anxiety; Arthroplasty, Replacement, | 2009 |
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Topics: Antipsychotic Agents; Benzodiazepines; Brazil; Cost-Benefit Analysis; Drug Costs; Haloperidol; Human | 2009 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.
Topics: Aged; Antipsychotic Agents; Botulinum Toxins, Type A; Bruxism; Clozapine; Dyskinesia, Drug-Induced; | 2010 |
Recurrence of hyperglycemic-induced chorea-ballismus after haloperidol withdrawal.
Topics: Aged, 80 and over; Antipsychotic Agents; Chorea; Haloperidol; Humans; Hyperglycemia; Male; Recurrenc | 2011 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol | 2012 |
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System St | 2012 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimul | 2003 |
Risperidone-induced leucopenia and neutropenia: a case report.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia, Vascular; Hallucinations; Halope | 2004 |
["Usual" cannabis abuse producing an unusual incident].
Topics: Adolescent; Antipsychotic Agents; Dyspnea; Eye Hemorrhage; Haloperidol; Humans; Male; Marijuana Abus | 2007 |
Endovascular cooling in a patient with neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Catheters, Indwelling; Creatine Kinase; Drug Synergism; Female; Fever; Haloper | 2008 |
Recurrent priapism during treatment with clozapine, quetiapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Male; Priapism; Que | 2007 |
Low serum neuroleptic levels predict relapse in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Male; Middle A | 1982 |
Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors.
Topics: Basal Ganglia; Basal Ganglia Diseases; Benzamides; Dose-Response Relationship, Drug; Female; Haloper | 1984 |
Bupropion in the treatment of psychotic depression: two case reports.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Hal | 1984 |
Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis.
Topics: Adult; Delusions; Hallucinations; Haloperidol; Humans; Male; Methamphetamine; Paranoid Disorders; Ps | 1983 |
Relapse in patients with shifting RDC diagnoses treated with lithium alone.
Topics: Adult; Bipolar Disorder; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Ha | 1982 |
Haloperidol (Serenace) use in 'childhood dislocation anxiety'.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; C | 1980 |
Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
Topics: Adult; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1994 |
Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
Topics: Adult; Age of Onset; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Logistic Mode | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Platelet aggregation and dense granule secretion in schizophrenia.
Topics: Adenosine Triphosphate; Adult; Age of Onset; Arachidonic Acid; Collagen; Haloperidol; Humans; Male; | 1994 |
Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
Topics: Adult; Anisotropy; Dose-Response Relationship, Drug; Erythrocyte Deformability; Erythrocyte Membrane | 1994 |
Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Recurrence; | 1995 |
Tics status.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administr | 1996 |
[Acute recurrent dystonia secondary to neuroleptic suppression].
Topics: Acute Disease; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Male; Middle Aged; Recurrence; S | 1997 |
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth | 1997 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic | 1998 |
The use of haloperidol and valproate in children with Sydenham chorea.
Topics: Adolescent; Alanine Transaminase; Anti-Dyskinesia Agents; Anticonvulsants; Aspartate Aminotransferas | 1998 |
Treatment of acute mania with topiramate.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug A | 1999 |
Cannabis and psychosis.
Topics: Adolescent; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Recurre | 2000 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
Occurrence of delusions during repetitive transcranial magnetic stimulation (rTMS) in major depression.
Topics: Delusions; Depressive Disorder, Major; Dopamine; Electric Stimulation Therapy; Electromagnetic Field | 2002 |
Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
Topics: Adult; Antipsychotic Agents; Anxiety; Arousal; Autonomic Nervous System; Basal Ganglia Diseases; Chl | 1979 |
Clinical features of chorea associated with systemic lupus erythematosus.
Topics: Adult; Azathioprine; Blood Sedimentation; Chlorpromazine; Chorea; Female; Haloperidol; Humans; Lupus | 1975 |
Recurrent neuroleptic malignant syndrome in a man with mild mental handicap.
Topics: Adult; Antipsychotic Agents; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1992 |
Treatment of hypomania following neuroleptic malignant syndrome.
Topics: Adult; Arousal; Bipolar Disorder; Drug Therapy, Combination; Electroconvulsive Therapy; Haloperidol; | 1992 |
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Topics: Administration, Oral; Adult; Brain; Dopamine; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Ps | 1992 |
Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation.
Topics: Adult; Depressive Disorder; Female; Haloperidol; Humans; Intellectual Disability; Neuroleptic Malign | 1992 |
[Psychotic episode caused by prevention of malaria with mefloquine. A case report].
Topics: Adult; Female; Hallucinations; Haloperidol; Humans; Malaria; Mefloquine; Perazine; Psychoses, Substa | 1992 |
Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Topics: Adult; Delta Rhythm; Electroencephalography; Female; Haloperidol; Humans; Male; Middle Aged; Recurre | 1992 |
Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Topics: Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; Haloperidol; Humans; Ireland; Male | 1991 |
Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
Topics: Acute Disease; Adult; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox | 1990 |
The course of a seasonal bipolar disorder influenced by caffeine.
Topics: Bipolar Disorder; Caffeine; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1991 |
Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Mi | 1990 |
[Protracted recurrent neuroleptic malignant syndrome].
Topics: Adult; Bromocriptine; Dantrolene; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Neu | 1990 |
CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Topics: Adult; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Homovanillic Acid; Humans | 1989 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
[Cytolytic episodes during cirrhosis].
Topics: Antipyrine; Anxiety Disorders; Barbiturates; Caffeine; Cholestasis; Drug Therapy, Combination; Femal | 1986 |
Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction.
Topics: Adult; Aged; Antipsychotic Agents; Biological Availability; Dose-Response Relationship, Drug; Halope | 1986 |
Comparative study of schizophrenic patients relapsed on and off medication.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Clozapine; Delayed-Action Preparations; Female; Haloper | 1987 |
Haloperidol and cardiac arrest.
Topics: Aged; Haloperidol; Heart Arrest; Humans; Male; Recurrence | 1988 |
Secondary mania from cerebral embolization with nonfocal neurologic findings.
Topics: Adult; Bipolar Disorder; Electroencephalography; Haloperidol; Humans; Intracranial Embolism and Thro | 1988 |
[Successful combined neuroleptic and lithium treatment of a chronic schizophrenic patient with recurrent aggressive behavior].
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Male; Recurrence; S | 1986 |
Bilateral ballism: a rare syndrome. Review of the literature and presentation of a case.
Topics: Adult; Cerebral Infarction; Electroencephalography; Female; Functional Laterality; Haloperidol; Huma | 1986 |
Treatment of Sydenham's chorea with haloperidol.
Topics: Adolescent; Child; Chorea; Female; Haloperidol; Humans; Male; Muscle Tonus; Recurrence | 1973 |
[Course of a schizophrenic process during a traumatic brain injury caused by cerebral fat emboli].
Topics: Adult; Brain Injuries; Embolism, Fat; Female; Haloperidol; Humans; Intracranial Embolism and Thrombo | 1973 |
The clinical picture and management of Gilles de la Tourette's syndrome.
Topics: Adolescent; Adult; Child; Chronic Disease; Dose-Response Relationship, Drug; Drug Tolerance; Female; | 1971 |
Airborne allergic contact dermatitis in a parquet fitter.
Topics: Air Pollutants, Occupational; Construction Industry; Dermatitis, Allergic Contact; Dermatitis, Occup | 2012 |